A Comparison of Exenatide and Insulin Glargine

Phase 4 Completed 44 enrolled The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a 16-week, Single-center, Randomized, Open Label, Parallel Controlled Group Comparison of the Comprehensive Glycemic Control of Exenatide and Insulin Glargine on Type 2 Diabetes Patients Inadequately Controlled With Metformin Monotherapy.

Timeline

Start: 2015-01
Primary completion: 2016-07
Completion: 2016-10

Publications

Yin TT, Bi Y, Li P, Shen SM, Wang WM, Jiang C, Gao CX, Wang Y, Gao LJ, Zhu DL, Feng WH. Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. Nutr Metab (Lond). 2018 Oct 1;15:67. doi: 10.1186/s12986-018-0295-6. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Exenatide	Peptide	10 ug	Subcutaneous
Comparator	insulin glargine	Protein / enzyme biologic	8 iu	Subcutaneous

A Comparison of Exenatide and Insulin Glargine

Summary

Timeline

Publications

Drugs

Indications